File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Surveillance of emerging drugs of abuse in Hong Kong: Validation of an analytical tool

TitleSurveillance of emerging drugs of abuse in Hong Kong: Validation of an analytical tool
Authors
Issue Date2015
Citation
Hong Kong Medical Journal, 2015, v. 21, n. 2, p. 114-123 How to Cite?
Abstract© 2015, Hong Kong Academy of Medicine Press. All rights reserved. Objective: To validate a locally developed chromatography-based method to monitor emerging drugs of abuse whilst performing regular drug testing in abusers. Design: Cross-sectional study. Setting: Eleven regional hospitals, seven social service units, and a tertiary level clinical toxicology laboratory in Hong Kong. Participants: A total of 972 drug abusers and high-risk individuals were recruited from acute, rehabilitation, and high-risk settings between 1 November 2011 and 31 July 2013. A subset of the participants was of South Asian ethnicity. In total, 2000 urine or hair specimens were collected. Main outcome measures: Proof of concept that surveillance of emerging drugs of abuse can be performed whilst conducting routine drug of abuse testing in patients. Results: The method was successfully applied to 2000 samples with three emerging drugs of abuse detected in five samples: PMMA (paramethoxymethamphetamine), TFMPP [1-(3-trifluoromethylphenyl)piperazine], and methcathinone. The method also detected conventional drugs of abuse, with codeine, methadone, heroin, methamphetamine, and ketamine being the most frequently detected drugs. Other findings included the observation that South Asians had significantly higher rates of using opiates such as heroin, methadone, and codeine; and that ketamine and cocaine had significantly higher detection rates in acute subjects compared with the rehabilitation population. Conclusions: This locally developed analytical method is a valid tool for simultaneous surveillance of emerging drugs of abuse and routine drug monitoring of patients at minimal additional cost and effort. Continued, proactive surveillance and early identification of emerging drugs will facilitate prompt clinical, social, and legislative management.
Persistent Identifierhttp://hdl.handle.net/10722/250338
ISSN
2021 Impact Factor: 1.256
2020 SCImago Journal Rankings: 0.357
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTang, Magdalene H.Y.-
dc.contributor.authorChing, C. K.-
dc.contributor.authorTse, M. L.-
dc.contributor.authorNg, Carol-
dc.contributor.authorLee, Caroline-
dc.contributor.authorChong, Y. K.-
dc.contributor.authorWong, Watson-
dc.contributor.authorMak, Tony W.L.-
dc.contributor.authorLam, Y. H.-
dc.contributor.authorCheung, W. H.-
dc.contributor.authorDunn, Eva-
dc.contributor.authorWong, C. K.-
dc.contributor.authorLo, Y. C.-
dc.contributor.authorLam, M.-
dc.contributor.authorLee, Michael-
dc.contributor.authorLau, Angus-
dc.contributor.authorChung, Albert K.K.-
dc.contributor.authorTam, Sidney-
dc.contributor.authorTam, Ted-
dc.contributor.authorLam, Vincent-
dc.contributor.authorTang, Hezon-
dc.contributor.authorWan, Katy-
dc.contributor.authorYeh, Mamre Lilian-
dc.contributor.authorWong, M. T.-
dc.contributor.authorShek, C. C.-
dc.contributor.authorTang, W. K.-
dc.contributor.authorChan, Michael-
dc.contributor.authorFung, Jeffrey-
dc.contributor.authorTsui, S. H.-
dc.contributor.authorLit, Albert-
dc.contributor.authorLeung, Joe-
dc.date.accessioned2017-12-28T07:57:23Z-
dc.date.available2017-12-28T07:57:23Z-
dc.date.issued2015-
dc.identifier.citationHong Kong Medical Journal, 2015, v. 21, n. 2, p. 114-123-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/250338-
dc.description.abstract© 2015, Hong Kong Academy of Medicine Press. All rights reserved. Objective: To validate a locally developed chromatography-based method to monitor emerging drugs of abuse whilst performing regular drug testing in abusers. Design: Cross-sectional study. Setting: Eleven regional hospitals, seven social service units, and a tertiary level clinical toxicology laboratory in Hong Kong. Participants: A total of 972 drug abusers and high-risk individuals were recruited from acute, rehabilitation, and high-risk settings between 1 November 2011 and 31 July 2013. A subset of the participants was of South Asian ethnicity. In total, 2000 urine or hair specimens were collected. Main outcome measures: Proof of concept that surveillance of emerging drugs of abuse can be performed whilst conducting routine drug of abuse testing in patients. Results: The method was successfully applied to 2000 samples with three emerging drugs of abuse detected in five samples: PMMA (paramethoxymethamphetamine), TFMPP [1-(3-trifluoromethylphenyl)piperazine], and methcathinone. The method also detected conventional drugs of abuse, with codeine, methadone, heroin, methamphetamine, and ketamine being the most frequently detected drugs. Other findings included the observation that South Asians had significantly higher rates of using opiates such as heroin, methadone, and codeine; and that ketamine and cocaine had significantly higher detection rates in acute subjects compared with the rehabilitation population. Conclusions: This locally developed analytical method is a valid tool for simultaneous surveillance of emerging drugs of abuse and routine drug monitoring of patients at minimal additional cost and effort. Continued, proactive surveillance and early identification of emerging drugs will facilitate prompt clinical, social, and legislative management.-
dc.languageeng-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleSurveillance of emerging drugs of abuse in Hong Kong: Validation of an analytical tool-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.12809/hkmj144398-
dc.identifier.pmid25756277-
dc.identifier.scopuseid_2-s2.0-84952792758-
dc.identifier.volume21-
dc.identifier.issue2-
dc.identifier.spage114-
dc.identifier.epage123-
dc.identifier.isiWOS:000353253600004-
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats